[HTML][HTML] Stopping anticoagulation in a woman with unprovoked venous thromboembolism
CMAJ| SEPTEMBER 5, 2017| VOLUME 189| ISSUE 35 E1113 patient-year; 95% confidence
interval [CI] 1.8%–4.8%). In highrisk patients who stopped treatment, the rate of venous …
interval [CI] 1.8%–4.8%). In highrisk patients who stopped treatment, the rate of venous …
[HTML][HTML] Meta-analysis of long-term risk of recurrent venous thromboembolism after stopping anticoagulation in men and women with first unprovoked venous …
Background: The optimal duration of anticoagulation after a first unprovoked venous
thromboembolism (VTE) is uncertain. Anticoagulant therapy is highly effective at reducing …
thromboembolism (VTE) is uncertain. Anticoagulant therapy is highly effective at reducing …
[HTML][HTML] Stopping anticoagulant therapy after an unprovoked venous thromboembolism
C Kearon - CMAJ, 2008 - Can Med Assoc
• Patients with a first episode of unprovoked venous thromboembolism have a high risk of
recurrence if they stop anticoagulant therapy (about 10% in the first year).• Randomized …
recurrence if they stop anticoagulant therapy (about 10% in the first year).• Randomized …
Minimizing recurrent venous thromboembolism
B Bikdeli, HM Krumholz - BMJ, 2019 - bmj.com
Anticoagulation is the cornerstone of management for acute venous thromboembolism
(VTE). After a provoked VTE event, standard anticoagulation is usually short term. The …
(VTE). After a provoked VTE event, standard anticoagulation is usually short term. The …
[CITATION][C] HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTE.
P Kruger, J Eikelboom - Annals of Internal Medicine, 2017 - europepmc.org
HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a
first unprovoked VTE. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
first unprovoked VTE. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
Background: Whether to continue oral anticoagulant therapy beyond 6 months after an
“unprovoked” venous thromboembolism is controversial. We sought to determine clinical …
“unprovoked” venous thromboembolism is controversial. We sought to determine clinical …
[HTML][HTML] Extended Follow-up of the Multi-Center Multi-National Prospective Cohort Study That Derived the “Men Continue and HERDOO2” Clinical Decision Rule …
Abstract Abstract 451 Introduction: To continue or discontinue OAC after 6 months of therapy
for VTE is one of the most important unanswered questions in VTE management. In 2007 …
for VTE is one of the most important unanswered questions in VTE management. In 2007 …
[HTML][HTML] Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: a multi-national cohort
Abstract Background Choosing short-term (3-6 months) or indefinite anticoagulation after a
first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical …
first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical …
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis
Introduction For patients with a first unprovoked venous thromboembolism (VTE), the optimal
duration of anticoagulation is a crucial clinical dilemma which has yet to be resolved. The …
duration of anticoagulation is a crucial clinical dilemma which has yet to be resolved. The …
[PDF][PDF] Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study
Objective To prospectively validate the HERDOO2 rule (Hyperpigmentation, Edema, or
Redness in either leg; D-dimer level≥ 250 μg/L; Obesity with body mass index≥ 30; or …
Redness in either leg; D-dimer level≥ 250 μg/L; Obesity with body mass index≥ 30; or …
